Basal Cell Nevus Syndrome Clinical Trial
Official title:
Pilot Trial Comparing Two Different Wavelengths of Light (Blue Versus Red) During Levulan™-Based Photodynamic Therapy of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome
Verified date | July 2020 |
Source | The Cleveland Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators will be testing whether aminolevulinate-based (Levulan™) Photodynamic Therapy (PDT) shows effectiveness in the treatment and prevention of cutaneous basal cell carcinoma (BCC) in Basal Cell Nevus Syndrome (BCNS) patients. Levulan™ PDT is an FDA-approved method widely used currently for squamous precancers of the skin. The investigators hypothesize that PDT will provide exceptional benefit in the BCNS population because PDT is nonmutagenic, nonscarring, and can be safely repeated many times. Additionally, the study will investigate whether there are any differences in tumor clearance between the Blu-U® (blue lamp) and Aktilite™(red lamp) therapies.
Status | Completed |
Enrollment | 3 |
Est. completion date | December 1, 2016 |
Est. primary completion date | September 1, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Men, women, and children of any age or ethnic group who meet eligibility - Patients under 18 years of age must be accompanied and co-consented, by a parent or legal guardian. - Patients must have a diagnosis of Basal Cell Nevus Syndrome (BCNS) - For diagnosis of BCNS, the patient must have either 2 major criteria, one major and two minor criteria, or one major criterion plus molecular confirmation of a PTCH1 gene mutation - Major criteria are: - (1) BCC prior to age 20 years, or excessive number of BCCs out of proportion to prior sun exposure and skin type - (2) keratocyst of the jaw prior to age 20 - (3) palmar or plantar pitting - (4) lamellar calcification of the falx cerebri - (5) medulloblastoma - (6) first degree relative with BCNS - Minor criteria are: - (1) rib anomalies, or other specific skeletal malformations including kyphoscoliosis and short 4th metacarpals - (2) macrocephaly - (3) cleft/lip or palate; - (4) fibroma of the heart or ovary - (5) ocular abnormalities - (6) other rare abnormalities - At least two BCC tumors, preferably more, located in different body regions or located greater than 10 cm apart in locations that can be reproducibly separated into red and blue illumination fields - Female subjects are not pregnant or nursing or planning to become pregnant during the study - Subjects must have the ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: - Pregnant, planning on getting pregnant or nursing - Currently participating in another clinical trial - Using any topical treatment for their BCC tumors, unless discontinued at least 1 month prior - Currently being treated for other cancers with medical or radiation therapy - Patients with a known hypersensitivity to 5-aminolevulinic acid or any component of the study material - Patients with a history of a photosensitivity disease, including porphyria cutanea tarda |
Country | Name | City | State |
---|---|---|---|
United States | Cleveland Clinic | Cleveland | Ohio |
Lead Sponsor | Collaborator |
---|---|
Edward Maytin, MD, PhD | DUSA Pharmaceuticals, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tumor Clearance Rate Following Red or Blue Light PDT | The rate of clearance of existing BCC tumors will be assessed in patients with BCNS, using clinical and photographic measurements. The endpoint will be assessed for tumors in a Red light treatment field and a Blue light treatment field in each patient, and compared (bilateral intrapatient comparison). | 6 months | |
Secondary | Pain During Illumination | Pain reported by the patient, using a 0-10 Visual Analog Scale (VAS), where 0 is no pain and 10 is maximum pain possible. | Maximum value reported during the illumination period | |
Secondary | Patient Satisfaction Survey | Overall patient satisfaction with the technique will be assessed using a simple survey: 6 = extremely satisfied; 5 = very satisfied; 4 = somewhat satisfied; 3 = somewhat dissatisfied; 2 = very dissatisfied; 1 = extremely dissatisfied. |
6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02550678 -
A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT00555633 -
Use of an SPF30 Sunscreen and an After-sun-lotion in Skin Cancer Risk Patients
|
N/A | |
Recruiting |
NCT03483441 -
Vitamin D and Photodynamic Therapy for Treatment of BCC in BCNS
|
Phase 1 | |
Active, not recruiting |
NCT03467789 -
Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma
|
Phase 1 | |
Recruiting |
NCT05463757 -
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
|
||
Completed |
NCT02762084 -
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
|
Phase 2 | |
Terminated |
NCT04308395 -
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
|
Phase 3 | |
Withdrawn |
NCT03767439 -
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
|
Phase 2 | |
Completed |
NCT04416516 -
Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor
|
Phase 2 | |
Recruiting |
NCT06330350 -
Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
|
||
Enrolling by invitation |
NCT06330324 -
Reproductive Options in Inherited Skin Diseases
|
||
Terminated |
NCT02303041 -
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02100371 -
Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome
|
N/A | |
Completed |
NCT03703310 -
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
|
Phase 3 | |
Completed |
NCT00957229 -
To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)
|
Phase 2 | |
Completed |
NCT01556009 -
Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
|
Phase 2 |